• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

提高胰腺癌外科治疗的成本效益:一项系统评价和成本荟萃分析,采用试验序贯分析。

Enhancing the cost-effectiveness of surgical care in pancreatic cancer: a systematic review and cost meta-analysis with trial sequential analysis.

机构信息

Department of Surgical Gastroenterology, SK Hospital, Thiruvananthapuram, India.

Department of Surgical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India.

出版信息

HPB (Oxford). 2022 Mar;24(3):309-321. doi: 10.1016/j.hpb.2021.11.004. Epub 2021 Nov 12.

DOI:10.1016/j.hpb.2021.11.004
PMID:34848126
Abstract

BACKGROUND

Clinical pathways (CP) based on Enhanced recovery after surgery (ERAS®) are increasingly utilised in patients undergoing pancreatoduodenectomy (PD). This systematic review aimed to compare the impact of CPs versus conventional care (CC) on peri-PD costs.

METHODS

A systematic review of major reference databases was undertaken. Quality assessment was performed using the CHEERS checklist. Incremental cost-effectiveness ratios were calculated as part of the cost-effectiveness analysis. A meta-analysis was performed using random-effects models and Trial sequential analysis (TSA) was used to assess the precision and conclusiveness of the results.

RESULTS

14 studies meeting inclusion criteria were included for full qualitative synthesis. All studies reported a reduction in overall costs, length of stay and overall complication rates for CPs when compared to CC. Meta-analysis performed on nine studies demonstrated significantly reduced costs in the CP group, with considerable heterogeneity (Pooled mean difference of $ 4.28 × 10, p < 0.01, I = 95%). Cost-effectiveness analysis in relation to complications demonstrated dominance of CPs over CC in being cheaper as well as more effective. TSA supported the cost benefit of enhanced-recovery CPs, displaying minimal type 1 error.

CONCLUSION

Peri-PD CPs result in significant cost-reduction in comparison to CC.

摘要

背景

基于术后加速康复(ERAS®)的临床路径(CP)越来越多地用于接受胰十二指肠切除术(PD)的患者。本系统评价旨在比较 CP 与常规护理(CC)对 PD 围手术期成本的影响。

方法

对主要参考数据库进行系统评价。使用 CHEERS 清单进行质量评估。作为成本效益分析的一部分,计算增量成本效益比。使用随机效应模型进行荟萃分析,并使用试验序贯分析(TSA)评估结果的精度和结论性。

结果

纳入了 14 项符合纳入标准的研究进行全面定性综合分析。与 CC 相比,所有研究均报告 CP 可降低总费用、住院时间和总体并发症发生率。对 9 项研究进行的荟萃分析表明 CP 组的成本显著降低,存在很大的异质性(CP 组的 pooled mean difference 为$4.28×10,p<0.01,I=95%)。与并发症相关的成本效益分析表明,CP 在更便宜的同时也更有效,因此优于 CC。TSA 支持增强型康复 CP 的成本效益,显示出最小的一类错误。

结论

与 CC 相比,PD 围手术期 CP 可显著降低成本。

相似文献

1
Enhancing the cost-effectiveness of surgical care in pancreatic cancer: a systematic review and cost meta-analysis with trial sequential analysis.提高胰腺癌外科治疗的成本效益:一项系统评价和成本荟萃分析,采用试验序贯分析。
HPB (Oxford). 2022 Mar;24(3):309-321. doi: 10.1016/j.hpb.2021.11.004. Epub 2021 Nov 12.
2
The influence of socioeconomic status on access to cancer care and survival in resectable pancreatic cancer: a systematic review and meta-analysis.社会经济地位对可切除胰腺癌患者获得癌症治疗和生存的影响:系统评价和荟萃分析。
ANZ J Surg. 2022 Nov;92(11):2795-2807. doi: 10.1111/ans.17964. Epub 2022 Aug 8.
3
4
Cost effectiveness after a pancreaticoduodenectomy: bolstering the volume argument.胰十二指肠切除术后的成本效益:强化手术量论据
HPB (Oxford). 2014 Dec;16(12):1056-61. doi: 10.1111/hpb.12309. Epub 2014 Jul 16.
5
Cost-effectiveness of minimally invasive pancreatic resection.微创胰腺切除术的成本效益。
J Hepatobiliary Pancreat Sci. 2018 Jun;25(6):291-298. doi: 10.1002/jhbp.558.
6
Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.高风险情况下的易栓症筛查:系统评价与成本效益分析。易栓症筛查的血栓形成:风险与经济评估(TREATS)研究。
Health Technol Assess. 2006 Apr;10(11):1-110. doi: 10.3310/hta10110.
7
Cost-benefit analysis of an enhanced recovery protocol for pancreaticoduodenectomy.胰十二指肠切除术强化康复方案的成本效益分析。
Br J Surg. 2015 Dec;102(13):1676-83. doi: 10.1002/bjs.9957. Epub 2015 Oct 22.
8
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗:一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
9
Cost and utilization impact of a clinical pathway for patients undergoing pancreaticoduodenectomy.胰十二指肠切除术患者临床路径的成本及使用影响
Ann Surg Oncol. 2000 Aug;7(7):484-9. doi: 10.1007/s10434-000-0484-0.
10
Systematic review and meta-analysis of enhanced recovery after pancreatic surgery with particular emphasis on pancreaticoduodenectomies.胰腺手术后加速康复的系统评价和荟萃分析,特别强调胰十二指肠切除术。
World J Surg. 2013 Aug;37(8):1909-18. doi: 10.1007/s00268-013-2044-3.

引用本文的文献

1
Cost-consequence analysis of the enhanced recovery after surgery protocol in major lung resection with minimally invasive technique (VATS).微创技术(电视辅助胸腔镜手术)下进行肺叶切除术的术后加速康复方案的成本-后果分析
Front Surg. 2024 Oct 30;11:1471070. doi: 10.3389/fsurg.2024.1471070. eCollection 2024.
2
Construction of sensitive quality indicators for rapid rehabilitation care of patients after combined pancreaticoduodenectomy.胰十二指肠联合切除术后患者快速康复护理敏感质量指标的构建
BMC Nurs. 2024 Sep 19;23(1):666. doi: 10.1186/s12912-024-02348-3.
3
Global Perceptions on ERAS in Pancreatoduodenectomy.
全球范围内对胰十二指肠切除术快速康复外科的认知。
World J Surg. 2023 Dec;47(12):2977-2989. doi: 10.1007/s00268-023-07198-9. Epub 2023 Oct 3.
4
Where Enhanced Recovery after Surgery (ERAS) Protocols Meet the Three Major Current Pandemics: COVID-19, Obesity and Malignancy.手术加速康复(ERAS)方案与当前三大流行病:COVID-19、肥胖症和恶性肿瘤的交集
Cancers (Basel). 2022 Mar 25;14(7):1660. doi: 10.3390/cancers14071660.